The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration
project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community.
Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco
and Fremont and will be provided Truvada to take orally once daily as PrEP.
Phase:
Phase 4
Details
Lead Sponsor:
Public Health Foundation Enterprises, Inc.
Collaborators:
API Wellness California HIV/AIDS Research Program San Francisco Community Health Center San Francisco Department of Public Health Tri-City Health Center University of California, San Francisco
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir